14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
GNPX vs NVS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Novartis AG (NVS) is the stronger overall head-to-head candidate over Genprex, Inc. (GNPX) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). GNPX carries a Unified Composite Score of 42.2/100 (HOLD) at $1.45 (N/M Forward P/E, 0.0% operating margin), whereas NVS carries 37.0/100 (SELL) at $150.47 (15.2x Forward P/E, 34.0% operating margin).
Composite vs. Pillar Nuance: While GNPX currently prints a higher short-term Unified Composite Score (42.2/100 HOLD vs. NVS 37.0/100 SELL), NVS captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (34.0% vs. 0.0% operating margin) and revenue trajectory (+4.7% vs. +0.0% YoY).
Technical & Structure Timing Caution: GNPX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.6); meanwhile NVS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 38.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GNPX vs NVS. Trailing 12-month operating profitability (GNPX 0.0% vs NVS 34.0%) and valuation multiples (GNPX N/M vs NVS 15.2x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $2.2M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
NVS Moat ProfileHigh-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $285.6B market capitalization and 34.0% operating margin.
OpEx & R&D Reinvestment41.2% of Rev ($16.7B)
90D Engineering Disclosures0 Published
Investor FAQ GNPX vs NVS Key Questions & Quantitative Answers
As of Nov 20, 2026, Novartis AG (NVS) is the stronger overall head-to-head candidate over Genprex, Inc. (GNPX) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). GNPX carries a Unified Composite Score of 42.2/100 (HOLD) at $1.45 (N/M Forward P/E, 0.0% operating margin), whereas NVS carries 37.0/100 (SELL) at $150.47 (15.2x Forward P/E, 34.0% operating margin). Composite vs. Pillar Nuance: While GNPX currently prints a higher short-term Unified Composite Score (42.2/100 HOLD vs. NVS 37.0/100 SELL), NVS captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (34.0% vs. 0.0% operating margin) and revenue trajectory (+4.7% vs. +0.0% YoY). Technical & Structure Timing Caution: GNPX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.6); meanwhile NVS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 38.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
NVS leads the Growth & Scale pillar: GNPX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with NVS at +4.7% YoY revenue growth and -68.8% YoY earnings growth on $40.5B TTM revenue (75.2% gross margin, 34.0% operating margin). On trailing 12-month operating scale, GNPX generates N/A in USD-normalized revenue versus $40.5B for NVS. In operating R&D and SG&A reinvestment, GNPX deploys N/A (0 90-day corporate R&D disclosures) versus 41.2% of Rev ($16.7B) (0 disclosures) for NVS.
NVS screens cheaper on headline valuation multiples. GNPX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas NVS trades at 15.2x Forward P/E, 28.9x Trailing P/E, 3.69x PEG, and 7.1x EV/Revenue (42.0% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GNPX (-233.7% ROE) versus NVS (24.3% ROE) capital efficiency.
In options market volatility and institutional positioning, GNPX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-4.68β · 96% Vol realized risk). By comparison, NVS carries 16.9% implied volatility (6th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.32β · 28% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.